Nabriva Therapeutics plc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nabriva Therapeutics plc.
US FDA Revisits Gonorrhea Drug Development As Fast-Emerging Resistance, Preclinical Challenges Hold Back New Products
From animal models to non-inferiority margins, US FDA is seeking new perspectives on gonorrhea R&D, including how to incorporate extragenital infections into clinical programs.
Only two new antibiotics are in Phase III trials for gonorrhea: Entasis’ zoliflodacin, in collaboration with the Global Antibiotic R&D Partnership, and GlaxoSmithKline’s gepotidacin in partnership with the US Biomedical Advanced R&D Authority.
Moving away from its earlier hospital-based focus with the novel antibiotic, Nabriva also thinks selling Merck & Co.’s Sivextro will provide complementary business.
The number of new drugs containing new active substances approved in the EU rose significantly in 2020, underpinned by a strong showing for orphan-designated products and a string of novel medicines for cancer and infectious diseases. Notable among the new clutch of approvals was the first ever COVID-19 vaccine, Pfizer/BioNTech's Comirnaty.
- Other Names / Subsidiaries
- Zavante Therapeutics, Inc.